NCT00539591 2025-12-23
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
Clinical Trials
25 trialsNCT05512481 2025-03-03
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05827770 2023-04-25
The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma
Fudan University
Phase 2 Unknown
NCT00602576 2022-06-14
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT04884997 2021-05-13
A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT01328535 2020-10-22
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT00505635 2020-09-24
Biochemotherapy With Temozolomide for Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00525031 2020-09-23
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04397770 2020-05-21
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00804908 2018-06-06
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
AbbVie
Phase 2 Completed
NCT00626405 2018-05-01
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00521001 2017-08-14
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00831545 2017-05-09
Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00588341 2016-02-01
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00673361 2016-01-13
Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma
Duke University
Phase 2 Terminated
NCT00885534 2015-05-06
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00338130 2014-08-13
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
AstraZeneca
Phase 2 Completed
NCT00568048 2013-04-10
Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Swiss Cancer Institute
Phase 2 Completed
NCT00072345 2013-01-18
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00072163 2013-01-17
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00104988 2012-08-22
S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT01048554 2012-04-19
MEL0107
Mt. Sinai Medical Center, Miami
Phase 2 Completed
NCT00991250 2010-02-05
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
SentoClone AB
Phase 2 Unknown
NCT00383851 2007-12-06
Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma
Attenuon
Phase 2 Unknown